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ABSTRACT 
 
Estrogen’s Impact on Colon Tumor Formation. (April 2010) 
 
Kirby Tinsley 
Department of Nutrition 
Texas A&M University 
 
Research Advisor: Dr. Clinton Allred 
Department of Nutrition 
 
 
One hundred thirty six men and women die every day from colon cancer in the United 
States (2008 statistics).  Estrogen has been shown to reduce colonic tumor inflammation; 
however, it is unclear in the tumor development and growth process what is the most 
effective time for estrogen treatment. To gain a complete understanding of estrogen’s 
chemopreventative effects, more research needs to be conducted. This study will 
demonstrate that when estrogen is given after colon tumors are fully initiated, the risk of 
the colon tumors continued growth is reduced.  Tumors were induced in ovariectomized 
mice using azoxymethane (AOM).  Ten weeks after tumors formed, an estrogen or 
control (VEH) pellet was inserted into the mice.  Ten weeks later, the tumors and the 
most distal uninvolved tissues were removed. Apoptosis and proliferation assays were 
completed on all tissues.  Results show that estrogen decreases colon tumor formation 
and area.  Apoptosis and proliferation data will be presented.  These data are important 
and have immediate clinical significance because estrogen therapy is most commonly 
used in post-menopausal women who are the highest risk of being diagnosed with colon 
cancer. 
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CHAPTER I 
 
INTRODUCTION 
 
Colon cancer is the third most prevalent cancer in the United States, as well as ranking 
third among cancer-related causes of death (1).  Colon cancer occurs in a higher 
percentage of men than women (2), possibly due to the presence of estrogen (E2) in 
women as a protective effect.   
 
Results from the Women’s Health Initiative study showed that post-menopausal women 
on hormone replacement therapy (HRT) had a lower incidence of colon cancer than 
those receiving placebo treatment (3).  A meta-analysis of eighteen epidemiologic 
studies showed a 20% decrease in colon tumor occurrence in postmenopausal women on 
HRT (4).  A cohort study recently conducted found that a reduced amount of E2 in 
menopausal cancer survivors was associated with an increased risk of a second colon 
tumor and they had a poorer prediction for recovery because these tumors were 
classified as grade 3 (one grade below the worst diagnosis) (5).  A large amount of 
clinical studies show that HRT and estrogen replacement therapy (ERT) can reduce the 
risk of colon cancer in post-menopausal women, but there is no difference in 
effectiveness of these two therapies (6-11).   
 
 
 
_______________ 
This thesis follows the style of Cancer Research. 
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The protective effects of E2 are also shown in animal data.  Smirnoff et al. found that rats 
injected with E2 had fewer colon tumors than the control group (12).  In another study, a 
metabolic precursor of E2 was able to reduce colon tumor occurrence following exposure 
to a carcinogen (13).  The ability of estrogen’s protective effects during the progression 
stage of colon cancer has been researched (14), but the majority of data from other 
studies, as well as from Dr. Allred’s lab (15 and 16), suggests that E2 would cause a 
decrease in formation of pre-malignant lesions after carcinogen exposure in mice.  
 
Constant inflammation in colonic epithelia is associated with an increased risk of tumor 
formation 17). This is shown by one of the most serious complications arising from 
inflammatory bowel disease (IBD) being colorectal cancer (18).  One area that more 
information is needed on is the possible effect E2 may have on tissue inflammation in the 
colon.  The inflammation being the cause of the cancer is shown through different 
characteristics of tumors in IBD patients vs. tumors in non-IBD patients (19).  Other 
studies have demonstrated that E2 can reduce inflammation in cells from other tissues 
(20), but no studies have focused on the effect it might have on cells from colon tissues. 
 
Recently, we completed an in vivo study in which E2’s influence on the development of 
inflammation-associated colon tumor formation was examined.  We found that E2 
reduced the number and size of colon tumors formed.  We present the analysis of the 
tissues collected from those animals and seek to conclude how E2 influences the cellular 
physiology of colon epithelial cells.  We will concentrate specifically on how E2 
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modifies cellular proliferation and programmed cell death (apoptosis), and this 
information will be presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
CHAPTER II 
MATERIALS AND METHODS 
 
Animal study information 
Mature female mice (C57BL/6) were ovariectomized before treatment so estrogen levels 
could be perfectly controlled.  Tumors were induced by injecting 12.5 mg/kg AOM 
(azoxymethane).  One week later, the first of two six-day treatments of 2.5% DSS 
(dextran sulphate sodium) in the mice’s drinking water began. The two treatments were 
separated by three weeks.  After 10 days of this treatment, an E2 implant (1 mg E2 and 
19 mg cholesterol) or VEH pellet (20 mg cholesterol) was inserted into the back of the 
neck of the mice.  The mice were killed ten weeks after the insertion of the pellet.  
Colons of the mice were cut out and the tumors and most distal uninvolved tissue were 
collected.  The tissues were fixed in 4% PFA (paraformaldehyde) for four hours and then 
treated with ethanol overnight. 
 
Apoptosis stain 
Millipore ApopTag peroxidase in situ Apoptosis Detection Kit was used. Manufactures’ 
instructions were followed with the following modifications: tissues were treated with 10 
ug/mL proteinase K for 3 minutes at 37oC and endogenous peroxidase was blocked 
using .3% hydrogen peroxide in methanol for 30 minutes. DAB (diaminobenzidine) was 
used as chromogen and nuclei were stained in .5% methyl green for 5 seconds.  Tissues 
were then cover slipped for analysis. 
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Proliferation stain 
 Endogenous peroxidase was quenched in .3% hydrogen peroxide in methanol for 30 
minutes then citrate buffer. Tissues were placed in microwave on high for 10 minutes 
and medium for 10 minutes for antigen retrieval.  The primary antibody was anti-brdu at 
1:20 dilution overnight at 40oC in humidified chamber.  The secondary antibody was 
goat anti-mouse HRP conjugated at 1:200 dilution for 1 hour at room temperature in 
humidified chamber.  DAB was used as chromogen. Tissues were counterstained in 
Meyers Hematoxylin for 15 seconds. Tissues were then dehydrated and cover slipped for 
analysis. 
 
Analysis 
All tissues were analyzed the same after staining. Pictures of all tissues were taken, data 
was blinded, and a percentage was calculated. For tumor tissues, up to 250 cells in each 
the four different regions of the tumor was counted and a mean percentage of 
apoptotic/proliferative cells per tumor was calculated. For normal tissue, one side of the 
crypts was counted until 20 crypts were evaluated and a mean percentage of 
apoptotic/proliferative cells were calculated. 
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CHAPTER III 
RESULTS 
In the uninvolved tissue of the C57BL/6 mice, estrogen showed a 0.5% increase in the 
amount of apoptosis compared to the VEH mice (Fig. 1).  The colon tumors that were 
removed were then analyzed to calculate the power of estrogen to promote apoptosis in 
formed tumors in comparison to the control mice. We found that the percentage of 
apoptotic cells was actually higher in the mice with the VEH pellet rather than the 
estrogen pellet (Fig. 2). A 0.5% difference for tumor apoptosis was calculated. 
Proliferation in the uninvolved tissue increased by 3.5% in the estrogen treated mice  
(Fig. 3). A p ≤ 0.05 was achieved in all of these results. The data shown here has mixed 
Figure 1. Apoptosis  in  the  colon  of  C57BL/6 mice. Female mice were ovariectomized and tumors
were  induced  by  a  12.5mg/kg  injection  of  AOM.   One  week  later,  mice  were  administered
the  first  of  two  six day  regiments  of 2.5%  dextran  sulfate  sodium  (DSS)  in  the  drinking  water.
Regiments were  separated  by  three  weeks.  Ten  days after the final  DSS  regiment,  animals
were  implanted  with  either  an  E 2 (1mg E2 + 19mg cholesterol)  or  VEH  (20mg cholesterol)  pellet.
Animals were sacrificed 10 weeks after the  final DSS treatment.  Values  are  mean percentage of
apoptotic cells per crypt +/-  standard error. Twenty crypts were evaluated per animal: n=6 animals in
the VEH  group  and  n=7  animals  in  the E2 group.
a
b
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Figure 2. Apoptosis  in  the  colon tumors of  C57BL/6 mice. Female mice were ovariectomized and
tumors  were  induced  by  a  12.5mg/kg  injection  of  AOM.   One  week  later,  mice  were
administered  the  first  of  two  six day  regiments  of 2.5%  dextran  sulfate  sodium  (DSS)  in  the
drinking  water.  Regiments were  separated  by  three  weeks.  Ten  days after the final  DSS
regiment,  animals  were  implanted  with  either  an  E 2 (1mg E2 + 19mg cholesterol)  or  VEH  (20mg
cholesterol)  pellet.   Animals were sacrificed 10 weeks after the  final DSS treatment.  Values  are
mean percentage of apoptotic cells per tumor +/-  standard error, 250 cells from four regions of each
tumor were evaluated: n=48 tumors in the VEH  group  and  n=50  tumors in  the E 2 group. Bars
without a common letter differ, p ²  0.05.
      a
   b
results of satisfaction to us. The increase of apoptotic cells in the uninvolved tissue was 
what we expected to see; however the two levels for estrogen treated tumors should have 
been more similar. The proliferation data from the uninvolved tissues is problematic. We 
are waiting for the analysis of proliferative cells in the tumors before any speculations 
are made as to why estrogen increased proliferation in uninvolved tissue.. Our studies 
demonstrated estrogen’s protective effects by reducing the overall number of 
adenocarcinomas (Fig. 4) present in estrogen treated mice, as well as showing that 
estrogen reduced the overall mean area of the tumors (Fig. 5).   
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Figure 3. Proliferation in  the  colon  of  C57BL/6 mice. Female mice were ovariectomized and
tumors  were  induced  by  a  12.5mg/kg  injection  of  AOM.   One  week  later,  mice  were
administered  the  first  of  two  six day  regiments  of 2.5%  dextran  sulfate  sodium  (DSS)  in  the
drinking  water.  Regiments were  separated  by  three  weeks.  Ten  days after the final  DSS
regiment,  animals  were  implanted  with  either  an  E 2 (1mg E2 + 19mg cholesterol)  or  VEH  (20mg
cholesterol)  pellet.   Animals were sacrificed 10 weeks after the  final DSS treatment.  Values  are
mean percentage of proliferative cells per crypt +/-  standard error. Twenty crypts were evaluated per
animal: n=6 animals in the VEH  group  and  n=7  animals  in  the E 2 group. Bars without a common
letter differ, p ²  0.05.
      a
   b
Figure 4. Tumors  in  the  colon  of  C57BL/6 mice. Female mice were ovariectomized and tumors
were  induced  by  a  12.5mg/kg  injection  of  AOM.   One  week  later,  mice  were  administered
the  first  of  two  six day  regiments  of 2.5%  dextran  sulfate  sodium  (DSS)  in  the  drinking  water.
Regiments were  separated  by  three  weeks.  Ten  days after the final  DSS  regiment,  animals
were  implanted  with  either  an  E2 (1mg E2 + 19mg cholesterol)  or  VEH  (20mg cholesterol)  pellet.
Animals were sacrificed 10 weeks after the  final DSS treatment.  Values  are  median  number of
tumors  per  animal  +/-   median  absolute  deviation,  n=6 animals in the VEH  group  and  n=7
animals  in  the E2 group.  Bars without a common letter differ, p ²  0.05.
     a
      b
                                      VEH                              E 2
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Figure 5. Tumors area  in  the  colon  of  C57BL/6 mice. Female mice were ovariectomized and
tumors  were  induced  by  a  12.5mg/kg  injection  of  AOM.   One  week  later,  mice  were
administered  the  first  of  two  six day  regiments  of 2.5%  dextran  sulfate  sodium  (DSS)  in  the
drinking  water.  Regiments were  separated  by  three  weeks.  Ten  days after the final  DSS
regiment,  animals  were  implanted  with  either  an  E 2 (1mg E2 + 19mg cholesterol)  or  VEH  (20mg
cholesterol)  pellet.   Animals were sacrificed 10 weeks after the  final DSS treatment.  Values  are
mean area of  tumors  +/-   standard error,  n=34 tumors in the VEH  group  and  n=29  tumors in  the
E2 group.  Bars without a common letter differ, p ²  0.05.
     a
      b
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CHAPTER IV 
CONCLUSION 
 
The mixed outcomes from other studies researching estrogen’s effects on colon cancer 
formation has led to the need for more studies to be conducted, specifically on how 
estrogen affects non-malignant colon cellular physiology. From our studies thus far, it is 
easy to see that estrogen has an impact on colon tumor formation. We have shown that 
estrogen’s presence in inflammation-associated colon tumors helps in the reduction of 
adenocarcinomas and mean area of tumors. After this positive outcome, we focused on 
proving that estrogen can alter physiology by inducing apoptosis and decreasing 
proliferation of the pre-cancerous cells. The apoptotic and proliferation data is mixed 
and thus may warrant more research. Estrogen changes the physiology of non-malignant 
cells to stop the transformation to malignant cells. The increase in percentage of 
apoptosis in the uninvolved tissue after estrogen treatment is what we wanted to see; 
however, the percentage difference in the tumor apoptosis is a little surprising. The 
tumor cell lines are non-responsive to estrogen treatment, so we expected to see the two 
levels stay the same after treating fully formed colon tumors with estrogen. Difference in 
this data and previous supports the idea that estrogen induces apoptosis in non-malignant 
colonocytes, but once the cells are cancerous estrogen no longer has an effect. We are 
waiting to calculate the percentage of proliferation in tumors before we try to come up 
with any final conclusion as to why estrogen treatment induced proliferation. We proved 
a definite protective effect of estrogen by showing its ability to reduce number and size 
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of colon tumors. That data has proved that estrogen is a chemopreventative agent. More 
research is needed to fully understand estrogen’s effects on colon epithelial cells. 
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